Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients

American Journal of Cardiology

Volumn 81, Issue 2, 1998, Pages 163-169

  Kloner, Robert A ^a   Vetrovec, George W ^b   Materson, Barry J ^b   Levenstein, Marcia ^b  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE; PLACEBO;

ADULT; ANGINA PECTORIS; ARTICLE; BLEEDING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG FORMULATION; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STROKE;

AMLODIPINE; CALCIUM CHANNEL BLOCKERS; CAUSE OF DEATH; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEMORRHAGE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NIFEDIPINE; PROSPECTIVE STUDIES; SAFETY; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 0032518835     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00868-0     Document Type: Article

References (15)

1. 1. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of CCBs associated with antihypertensive drug therapies. JAMA 1995; 224:620-625.
2. 2. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested. JAMA 1995;224:654-655.
3. 3. Kloner RA. Nifedipine in ischemic heart disease. Circulation 1995;92:1074-1078.
4. 4. Gustafson TL. TRUE EPISTAT Reference Manual. 5th ed. Chap. 9. Richardson, TX: Epistat Services; 1994.
5. 5. Kannel WB, Gordon T, eds. The Framingham Study. An epidemiologic investigation of cardiovascular disease. February, 1974. Department of Health, Education, and Welfare publication no. (NIH) 74-599.
6. 6. Hoes AW, Grobbee DE, Lubsen J. Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension. J Hypertens 1995;13: 805-811.
7. 7. Grimm RH Jr, Cohen JD, Smith WM, Falvo-Gerard L, Neaton JD, and the Multiple Risk Factor Intervention Trial Research Group. Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT): six-year intervention results for men in special intervention and usual care groups. Arch Intern Med 1985;145:1191-1199.
8. 8. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985;291:97-104.
9. 9. Helgeland A. Treatment of mild hypertension: a five-year controlled drug trial. The Oslo Study. Am J Med 1980;69:725-732.
10. 10. Muller JE, Morrison J, Stone PH, Rude RE, Rosner B, Roberts R, Pearle DL, Turi ZG, Schneider JF, Serfas DH, Tate C, Scheiner E, Sobel BE, Hennekens CH, Braunwald E. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation 1984;69:740-747.
11. 11. Alderman MH, Cohen H, Roqué R, Madhaven S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997;349:594-598.
12. 12. Pahor M, Guralnik JM, Corti M-C, Foley DJ, Corbonin P, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:1191-1197.
13. 13. Packer M, O'Connor CM, Ghali JK, Pressler ME, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL, for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114.
14. 14. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman B, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L, for the Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation 1997;96:856-863.
15. 15. Staessen JA, Fagard R, Thijs L, Cells H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-764.